Teva Pharmaceutical Industries Limited (TEVA) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, Teva Pharmaceutical Industries Limited (NYSE: TEVA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $40.70 (-3.30% 1D, market cap $49.05B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, TEVA ranks #153 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TEVA carries a Roarable C- (61/100 RQD), trailing P/E of 34.3x, gross margin of 51.8%, and ROIC of 9.4%. By comparison, ONC (BeOne Medicines Ltd.) holds a B- grade (71/100 RQD, P/E 147.2x, ROIC 10.5%, cap $42.11B) and RPRX (Royalty Pharma plc (Class A)) posts a B+ grade (76/100 RQD, P/E 49.2x, ROIC 7.0%, cap $38.63B). Among the 5-stock peer group, TAK leads on earnings multiple (32.8x) while ONC leads on capital efficiency (10.5% ROIC).
Per TEVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818686), Teva Pharmaceutical Industries Limited generated $17.26B in revenue (+4.3% YoY), $1.41B in net income, and $872.4M in free cash flow against $40.75B in total assets and $14.78B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±6% realized swing band)
Altman Z-Score 1.02 (DISTRESS RISK (<1.8)) • Piotroski F-Score 8/9
Capital intensity & 12.5% operating margin leave 11 pts on the table
Even with a 61/100 (C-) score, TEVA faces multiple-compression risk if 34.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($39.34) or 200D SMA ($34.73) invalidates the momentum regime and cuts Target Base ($41.25) toward Bear Floor ($32.18).
Teva Pharmaceutical Industries Limited (TEVA) dropped -3.30% to $40.70, trading at 92% of its 52-week range ($20.11 – $42.59). Solid 51.8% gross margin (9% return on capital), mixed timing at 34x P/E—hold if owned, no rush to chase.
Yahoo Finance report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Reuters report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Analysts initiated bullish coverage on Janus Living, GameStop, SharkNinja, Teva and H2O America, with targets of $33, $33, $245, $52 and $67.
HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $52.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TEVA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TEVA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Teva Pharmaceutical Industries Limited (TEVA) ranks #153 by composite RQD confidence (61/100, grade C-) and #39 by equity capitalization ($49.05B). Within this direct 5-issuer industry benchmark cohort, TAK leads on earnings valuation at 32.8x trailing P/E, while ONC leads on capital efficiency and profitability with 10.5% ROIC and 87.5% gross margin. RPRX currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with TEVA at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TEVA
ACTIVE
Teva Pharmaceutical Industries Limited | C- | 61/100 | 34.3x | 51.8% | 9.4% | -3.30% | $49.05B | Benchmark Subject |
| ONC BeOne Medicines Ltd. | B- | 71/100 | 147.2x | 87.5% | 10.5% | -2.45% | $42.11B | /onc-vs-teva → |
| RPRX Royalty Pharma plc (Class A) | B+ | 76/100 | 49.2x | — | 7.0% | -0.98% | $38.63B | /rprx-vs-teva → |
| TAK Takeda Pharmaceutical Company Limited American | B- | 71/100 | 32.8x | — | 9.9% | -0.19% | $66.07B | /tak-vs-teva → |
| GMAB Genmab A/S ADS | B- | 70/100 | 32.8x | — | 9.9% | -3.75% | $35.61B | /gmab-vs-teva → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Teva Pharmaceutical Industries Limited (TEVA) reported GAAP revenue of $17.26B (+4.3% vs. FY2024 revenue of $16.54B , and +8.9% cumulative change since FY2023) , GAAP net income of $1.41B, operating cash flow of $1.65B, and free cash flow of $872.4M (+73.6% YoY). On the balance sheet, TEVA closed FY2025 with $40.75B in total assets against $14.78B in total debt (Altman Z-Score: 1.02, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $17.26B | $1.41B | $1.65B | $872.4M | $40.75B | $14.78B |
| FY2024 (FY) | 2024-12-31 | $16.54B | -$1.64B | $1.25B | $502.5M | $39.33B | $15.12B |
| FY2023 (FY) | 2023-12-31 | $15.85B | -$559.0M | $1.37B | $654.9M | $26.58B | $6.22B |
As of 2026-11-03, Teva Pharmaceutical Industries Limited (NYSE: TEVA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $40.70 (-3.30% 1D, market cap $49.05B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, TEVA ranks #153 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TEVA carries a Roarable C- (61/100 RQD), trailing P/E of 34.3x, gross margin of 51.8%, and ROIC of 9.4%. By comparison, ONC (BeOne Medicines Ltd.) holds a B- grade (71/100 RQD, P/E 147.2x, ROIC 10.5%, cap $42.11B) and RPRX (Royalty Pharma plc (Class A)) posts a B+ grade (76/100 RQD, P/E 49.2x, ROIC 7.0%, cap $38.63B). Among the 5-stock peer group, TAK leads on earnings multiple (32.8x) while ONC leads on capital efficiency (10.5% ROIC).
Per TEVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818686), Teva Pharmaceutical Industries Limited generated $17.26B in revenue (+4.3% YoY), $1.41B in net income, and $872.4M in free cash flow against $40.75B in total assets and $14.78B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
TEVA last traded at $40.70 (-3.30% on volume of 10,587,244 shares), positioning the stock +3.46% above its 50-day simple moving average ($39.34) and +17.19% above its 200-day simple moving average ($34.73). Across its 52-week range of $20.11 to $42.59, TEVA sits at the 91.6% percentile with a 14-day RSI of 62.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.0% ($38.26 to $43.14).
Teva Pharmaceutical Industries Limited (TEVA) earns a live Roarable RQD composite score of 61/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $40.70 (-3.30% 1D, market capitalization $49.05B).
Teva Pharmaceutical Industries Limited is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It is a US-listed pharmaceutical company. Per the news wire, the company is described as transitioning from generics toward higher-margin branded drugs, and recent FDA approval of a monthly schizophrenia injection (Weltruza) is reported.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Teva Pharmaceutical Industries Limited (TEVA) reported $17.26B in annual revenue (up from $16.54B in FY2024, +4.3% YoY) and $1.41B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($15.85B revenue, -$559.0M net income) through FY2025, TEVA scaled operating cash flow to $1.65B and free cash flow to $872.4M, backed by $40.75B in total assets against $14.78B in total debt.
— for upstream/downstream dependencies, sector correlations, or 2nd-order bottlenecks beyond the sector classification (Health Care / Biotechnology: Pharmaceutical Preparations). A prospective investor should note that the leverage figures (Debt/Equity 1.74; debt of $14.
Real-time company headlines, analyst actions, and sector developments for Teva Pharmaceutical Industries Limited (TEVA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Reuters report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Teva Pharmaceutical Industries Limited (TEVA) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating Teva Pharmaceutical Industries Limited (TEVA). Institutional accumulation (Whale pillar 18/20) and a reported swing to $1.41B net income in FY 2025, plus the Weltruza FDA approval, support the momentum case.. With an RQD score of 61/100 (C-) and Forensic Balance Sheet at 12/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $45.46.
Both sides have a point here — TEVA's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Careful chasing TEVA at $42.09. A 34.3x trailing P/E, 1.81% FCF yield, Altman Z of 1.02, and Debt/Equity of 1.74 leave little valuation or balance-sheet cushion.. Gross margin is 51.8%, but operating margin is 12.5%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $36.20 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).